Clinical Trials Browser

Phase 3 × Recruiting × pembrolizumab × Clear all

NCT06151574 2026-03-18

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

Lung Neoplasms

NCT06422806 2026-03-18

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Phase 3 Recruiting

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Phase 3 Recruiting

Carcinoma, Transitional Cell

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT07061977 2026-03-18

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Phase 3 Recruiting

Locally Advanced Cervical Adenocarcinoma

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04267848 2026-03-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT06345729 2026-03-16

KANDLELIT-004

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06357533 2026-03-16

TROPION-Lung10

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT07190248 2026-03-16

KANDLELIT-007

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06170788 2026-03-13

TroFuse-007

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-03-13

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06312176 2026-03-13

MK-2870-010

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT06393374 2026-03-13

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Phase 3 Recruiting

Triple Negative Breast Neoplasms

NCT06422143 2026-03-13

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06556563 2026-03-13

EF-41

Phase 3 Recruiting

Glioblastoma

NCT06841354 2026-03-13

TroFuse-011

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT06875310 2026-03-13

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06952504 2026-03-13

TroFuse-033

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07216703 2026-03-13

TroFuse-036

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT06077760 2026-03-12

INTerpath-002

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06119581 2026-03-12

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06793215 2026-03-12

Krascendo 2

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06989112 2026-03-12

DE-01

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT06623422 2026-03-11

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06901531 2026-03-11

LUCERNA

Phase 3 Recruiting

Adenocarcinoma, Neoplasms

NCT05239741 2026-03-10

MK-3475-C66

Phase 3 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT07198074 2026-03-10

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT07218380 2026-03-06

FORAGER-2

Phase 3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05812807 2026-03-04

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Phase 3 Recruiting

Anatomic Stage I Breast Cancer AJCC v8

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06661720 2026-03-04

STRIKE

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT06890598 2026-03-03

SUNRAY-02

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06452277 2026-03-02

SOHO-02

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT06868277 2026-03-02

ARTEMIDELung04

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07026474 2026-03-02

RePaIr-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05920356 2026-02-27

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Phase 3 Recruiting

Melanoma, Nevus, Blue

NCT06692738 2026-02-25

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06282575 2026-02-24

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06767514 2026-02-24

HARMONi-7

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06525220 2026-02-23

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT06627647 2026-02-12

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Phase 3 Recruiting

Non-squamous Non-small Cell Lung Cancer

NCT05815927 2026-02-02

PROLoNg

Phase 3 Recruiting

Oligometastatic Squamous Cell Carcinoma of the Head and Neck

NCT04339218 2026-01-30

CRYOMUNE

Phase 3 Recruiting

Adenocarcinoma of Lung

NCT07222566 2026-01-23

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis